Drug Overview
Saphris (Allergan/Lundbeck/Meiji Seika) contains the atypical antipsychotic asenapine, which acts as a dopamine D2 and serotonin 5-HT2A antagonist. The drug was originally developed by Organon and Schering-Plough, and became part of Merck & Co’s portfolio after the company’s $41bn acquisition of Schering-Plough in 2009.
Saphris received US approval for its first bipolar disorder indication in August 2009 and was launched in the US in October 2009. In September 2010, asenapine received its first EU approval, where Lundbeck retains all commercial rights to the brand. Lundbeck launched asenapine (under the brand name Sycrest) in the EU in April 2011. In December 2013, Allergan (formerly Forest Laboratories) announced that it would acquire exclusive rights from Merck & Co for Saphris in the US. The deal closed in January 2014.
Allergan indicated additional approvals for bipolar depression and maintenance, as well as the launch of a new lower dose for Saphris, in the first quarter of 2017. However, Saphris’s US label does not reflect the drug’s approval in bipolar depression.
Saphris (Allergan/Lundbeck/Meiji Seika) contains the atypical antipsychotic asenapine, which acts as a dopamine D2 and serotonin 5-HT2A antagonist. The drug was originally developed by Organon and Schering-Plough, and became part of Merck & Co’s portfolio after the company’s $41bn acquisition of Schering-Plough in 2009.
Saphris received US approval for its first bipolar disorder indication in August 2009 and was launched in the US in October 2009. In September 2010, asenapine received its first EU approval, where Lundbeck retains all commercial rights to the brand. Lundbeck launched asenapine (under the brand name Sycrest) in the EU in April 2011. In December 2013, Allergan (formerly Forest Laboratories) announced that it would acquire exclusive rights from Merck & Co for Saphris in the US. The deal closed in January 2014.
Allergan indicated additional approvals for bipolar depression and maintenance, as well as the launch of a new lower dose for Saphris, in the first quarter of 2017. However, Saphris’s US label does not reflect the drug’s approval in bipolar depression.
Table of Contents
OVERVIEWDrug Overview
Product Profiles
Saphris: Bipolar disorder
Saphris: Schizophrenia
List of Figures
Figure 1: Saphris for bipolar disorder - SWOT analysis
Figure 2: Drug assessment summary for Saphris in bipolar disorder
Figure 3: Drug assessment summary for Saphris in bipolar disorder
Figure 4: Saphris for schizophrenia - SWOT analysis
Figure 5: Drug assessment summary of Saphris for schizophrenia
Figure 6: Drug assessment summary of Saphris for schizophrenia
Figure 7: Saphris sales for schizophrenia across the US, Japan, Germany, Italy, Spain, and the UK, by country, 2017-26
List of Tables
Table 1: Saphris bipolar disorder indication approvals
Table 2: Saphris drug profile
Table 3: Saphris pivotal trial data for the acute treatment of manic episodes in bipolar disorder
Table 4: Adverse events in =5% of Saphris-treated adult patients with bipolar mania in double-blind, placebo-controlled trials
Table 5: Adverse events in =5% of Saphris-treated adult patients with bipolar mania in a double-blind, placebo-controlled trial
Table 6: Trial data for Saphris as a maintenance therapy
Table 7: Overview of key pivotal trial data for Saphris in pediatric bipolar disorder patients
Table 8: Adverse reactions in =5% of Saphris-treated pediatric patients (10-17 years) with bipolar mania in a double-blind, placebo-controlled trial
Table 9: Saphris drug profile
Table 10: Saphris pivotal trial data in schizophrenia
Table 11: Saphris sales for schizophrenia across the US, Japan, Germany, Italy, Spain, and the UK, by country ($m), 2017-26
